Myriad Genetics, Inc. (MYGN) Tops Q1 EPS by 22c; Boosts Buyback, FY13 Outlook

November 5, 2013 4:14 PM

Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q1 EPS of $0.68, $0.22 better than the analyst estimate of $0.46. Revenue for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found